Early trial tests vaccine to turn immune system against rare cancers
NCT ID NCT03879694
Summary
This early-stage study tested the safety of an experimental cancer vaccine called SurVaxM in 19 patients with advanced neuroendocrine tumors that had spread. The vaccine aims to teach the body's immune system to recognize and attack cancer cells by targeting a specific protein they produce. Researchers monitored patients for side effects and checked if the treatment triggered an immune response against their tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG ATYPICAL CARCINOID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.